Skip to content

Efficacy of Laser Debridement on Pain and Bacterial Load in Chronic Wounds

CompletedNot applicableNCT03182582
View the official record on ClinicalTrials.gov

Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.

This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.

Brief summary (from the registry)

Bacterial load is frequently associated with impaired healing of chronic wounds. As well, sharp debridement is often associated with pain, causing patient distress, and thereby occasionally contributing to inadequacy of debridement, leading to a delay in wound healing. The purpose of this study is to assess the efficacy of the Sciton Laser in reducing bacterial load and patient distress in patients with chronic wounds, in efforts to expedite the wound healing process.

Study details

Official title
Efficacy of the Er:YAG Laser Debridement on Patient-Reported Pain and Bacterial Load in Chronic Wounds
Conditions
  • Wound Open
  • Chronic Venous Hypertension (Idiopathic) With Ulcer
  • Diabetic Foot Ulcer
Interventions
  • Device: Erbium:Yttrium-Aluminum-Garnet (Er:YAG) Laser Debridement
  • Procedure: Scalpel/Curette Debridement
Sponsor
Stanford University
Start date
2017-01-05
Primary completion
2017-03-17
Sex
All
Age range
from 18 Years
Results posted
Yes, on ClinicalTrials.gov
Total sites listed
0

Eligibility criteria

Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Aged eighteen years or older * Having a chronic wound (as defined by lack of at least 50% reduction in wound surface area over a period of four weeks) * No clinical evidence of active wound bed infection * No exposure of any vital structure (i.e., tendon, bone, vessel) * Has signed the informed consent form prior to any study protocol related procedure * Willing and able to adhere to protocol requirements Exclusion Criteria: * Any unstable medical condition that would cause the study treatment to be detrimental to the subject, as judged by the Principle Investigator * Documented medical history of significant cardiac, pulmonary, gastrointestinal, endocrine (other than Diabetes Mellitus type 1 or 2), metabolic, neurological, hepatic or nephrologic disease would impede the subject's participation, as judged by the Principle Investigator * Documented medical history of immunosuppression, immune deficiency disorder, or currently using immunosuppressive medications * Having clinical presentation of active osteomyelitis * Pregnancy or lactation * Participation in another clinical study involving ulcers within thirty days prior to enrollment

Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT03182582